Bio-TechneTECH
About: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Employees: 3,100
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
262% more call options, than puts
Call options by funds: $16.9M | Put options by funds: $4.67M
150% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 10 (+6) [Q3]
6% more capital invested
Capital invested by funds: $11.5B [Q2] → $12.2B (+$696M) [Q3]
2% less funds holding
Funds holding: 564 [Q2] → 550 (-14) [Q3]
5.67% less ownership
Funds ownership: 102.0% [Q2] → 96.34% (-5.67%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 187 | Existing positions reduced: 209
19% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 73
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Scotiabank Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target | 20%upside $88 | Sector Outperform Maintained | 31 Oct 2024 |
Baird Catherine Schulte 29% 1-year accuracy 6 / 21 met price target | 15%upside $84 | Outperform Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 11 articles about TECH published over the past 30 days
